Miriam E. Tucker is a writer and journalist specializing in medicine and health. She has been living with type 1 diabetes since 1973, giving her a unique perspective on the topics she covers. Miriam's work has been featured in various publications, including Guidelines Co, MDEdge, Knowledia, Medscape, and The diaTribe Foundation.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Miriam E. Tucker's coverage primarily focuses on health, healthcare & pharmaceuticals, and scientific topics with an emphasis on citing data. She seems to be interested in research findings and regulatory updates within the medical field.
To effectively reach out to Miriam, consider providing her with access to authoritative sources or researchers who can offer insights into the latest developments in diabetes, medical research methodologies and results, obesity treatments, thyroid disease management strategies, as well as advancements in bariatric surgery procedures.
As she cites data extensively in her articles, ensure that any pitches provide robust evidence-based information or refer to credible studies related to the specific topics covered by Miriam.
This information evolves through artificial intelligence and human feedback. Improve this profile .
SAN ANTONIO — Weight loss treatments aren’t reaching many of the people who need them most because of coverage barriers, new data suggested.
Most patients with rheumatoid arthritis or spondyloarthritis had significant antibody responses to COVID vaccine boosters, whether or not their immunomodulatory medications were held.
Real-world data show reduction in use of urate-lowering therapy among people with type 2 diabetes using SGLT2 inhibitors.
By: Miriam E. Tucker
WASHINGTON — Use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduced the need for urate-lowering therapy (ULT) and gout flare therapies in people who had both type 2 diabetes (T2D) and gout, new research has found.
By: Miriam E. Tucker
WASHINGTON — There is no benefit to interrupting treatment with many of the available targeted synthetic or biologic disease-modifying antirheumatic drugs for rheumatoid arthritis (RA) or spondyloarthritis (SpA) at the time of a repeat COVID-19 vaccine dose, new research found.
TOPLINE: Weight loss induced by an 8-week low-calorie diet resulted in an increase in serum 25-hydroxyvitamin D [25(OH)D] level in both women and men.
SAN ANTONIO — Oral semaglutide 25 mg appears to be just as effective in promoting weight loss and other beneficial outcomes as are the investigational 50-mg oral dose and the injectable 2.4-mg dose (Wegovy), in new research.
Large database study finds no increase in mortality, although other endpoints haven’t yet been reported, and the findings might not apply to those with active disease.
By: Miriam E. Tucker
WASHINGTON — Immune checkpoint inhibitor (ICI) therapy does not increase mortality in people with preexisting autoimmune diseases, new research has found.
(833) 317-6278 
